Similar articles

• Viral resistance: a major challenge in managing HIV disease.

  Boucher CA, Reedijk M. Boucher CA, et al. J Biol Regul Homeost Agents. 1995 Jul-Sep;9(3):91-4. J Biol Regul Homeost Agents. 1995. PMID: 8782014 Review. No abstract available.
• [Human immunodeficiency virus and antiretroviral therapy resistance].

  Quirós E, Torti C, Carosi G. Quirós E, et al. Enferm Infecc Microbiol Clin. 2000 May;18(5):234-7. Enferm Infecc Microbiol Clin. 2000. PMID: 10974768 Review. Spanish. No abstract available.
• Salvage therapy for patients failing their current antiretroviral regimen.

  Albrecht MA. Albrecht MA. AIDS Clin Rev. 2000-2001:139-91. AIDS Clin Rev. 2000. PMID: 10999220 Review. No abstract available.
• Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.

  Monno L, Appice A, Cavaliere R, Scarabaggio T, Angarano G. Monno L, et al. J Infect Dis. 1999 Aug;180(2):568-71. doi: 10.1086/314909. J Infect Dis. 1999. PMID: 10395885 No abstract available.
• Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.

  Kuritzkes DR, Sevin A, Young B, Bakhtiari M, Wu H, St Clair M, Connick E, Landay A, Spritzler J, Kessler H, Lederman MM. Kuritzkes DR, et al. J Infect Dis. 2000 Feb;181(2):491-7. doi: 10.1086/315244. J Infect Dis. 2000. PMID: 10669331 Clinical Trial.